---
6A = THE UNIVERSITY DAILY KANSAN
NEWS
WEDNESDAY, OCTOBER 9, 2002
Kansas City health system splits
The Associated Press
KANSAS CITY, Mo. — The Kansas City area's second-largest health system is dissolving its partnership, saying changes in the health care industry make the merger unnecessary.
St.Luke's-Shawnee Mission Health System and Shawnee Mission Medical Center hospitals will dissolve their six-year partnership on Nov. 1, officials of the hospitals said.
The split was not expected to affect patients and should not cause any job cuts, said G. Richard Hastings, president and chief executive officer of St. Luke's-Shawnee Mission Health System and Sam Turner, president and chief executive
officer of Shawnee Mission
Hastings said most managed-care plans no longer put tight restrictions on which hospitals their members can use. That meant a health system of numerous hospitals did not carry the clout it did in the past, he said.
John Leafier, an Overland Park-based health care consultant, said the St. Luke's-Shawnee Mission dissolved was part of a trend among non-profit health systems around the country.
Leafier said the dissolution was more of a comment on the rapidly changing health-care environment than on either organization.
"Whereas this type of business relationship appeared to make
tremendous sense a mere five years ago, it is less called for today," he said.
Hastings and Turner both said the two-hospital systems were stronger because of their merger, both in patient load and financially.
"St. Luke's is in the best financial condition it has ever been in," he said, noting the hospital would double the size of its north Kansas City campus, was planning a Lee's Summit campus and was making preliminary plans to expand St. Luke's South in Overland Park.
Turner said Shawnee Mission was planning $70 million to $80 million worth of expansions and improvements in the next five years, including a new 93-bed
critical-care tower.
Turner said the dissolution of the St. Luke's-Shawnee Mission partnership had to be dissolved for that transfer to occur.
As part of the agreement, the ownership of the 383-bed Shawnee Mission Medical Center will pass from Adventist Health Mid America to Adventist Health System, which is based in Winter Park, Fla.
"Because Shawnee Mission assets will go on the books of Adventist Health System, they wanted to make sure they did not have a middleman between us and Adventist Health System," said Turner, who added that Shawnee Mission Medical Center would continue to operate with a large degree of autonomy.
Peltier seeks reduction of sentence
The Associated Press
ST. PAUL, Minn. — An attorney for imprisoned American Indian activist Leonard Peltier asked a federal appeals court yesterday to reduce his sentence for the 1975 murders of two FBI agents and let him go free on parole.
Peltier's attorney, Eric Seitz, said the consecutive life sentences are unjust because important evidence was suppressed during Peltier's 1977 trial, and the sentences should have been imposed concurrently instead.
That would have made Peltier
eligible for parole 10 years ago. Seitz said.
Peltier, 57, has served 26 years in prison. He's currently in the federal prison at Leavenworth, Kan., and he's not due to get a full parole hearing until 2008. The Appeals Court is considering Peltier's appeal of a lower court ruling that denied his bid for resentencing. The Appeals Court did not immediately rule on his request.
"We're making a limited argument here today that enough is enough, that Leonard has served enough time, that the sentences he was given at the time should not have been meted out in that
fashion, and that by any sense of justice Leonard should be made eligible for parole and should be released as soon as possible." Seitz said outside the courthouse.
But retired prosecutor Lynn Crooks, who argued the government's case against Peltier more than 25 years ago, told the three-judge appeals panel that none of the facts have changed and Peltier's sentence is justified.
Peltier, a member of the American Indian Movement, was convicted in the June 26, 1975, murders of agents Ron Williams and Jack Coler at a time of high tension on the Pine
Ridge Indian Reservation in South Dakota.
Both agents were shot in the head at point-blank range after they were injured. The bodies were left on a dirt road.
Two suspects were acquitted and a third was freed for lack of evidence.
Peltier's supporters say the government falsified evidence leading to his arrest and coerced false testimony or hid evidence to obtain his conviction - claims the government denies.
Just before leaving office, President Clinton considered granting Peltier clemency but decided against it.
Graduate and undergraduate courses are available.
Need one last course? Enroll anytime!
KU INDEPENDENT STUDY offers more than 160 online and print courses
ENROLL ONLINE
Call 864-KUCE Or visit the Continuing Education Building 1515 St. Andrews Drive
www.kuce.org/isc
HE DID AND JUST LOOK AT HIM NOW...
NAT'L COMING
OUT DAY FRI.
OCT 11TH
AT THE ECM
BUILDING
12TH & OREAD
9:00PM
BYOB
FREE FOOD!
TWO FLOORS
Depo-Provera
medroxyprogesterone acetate injectable suspension
Contraceptive Injection
DEPO-PROVERA* Contraceptive Inject
DEPO-PROVERA® Contraceptive injection
(midopregnanone acetate) acute suspension, USP
This product is intended to prevent pregnancy. it does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
What is DEPO-PROVERA Contraceptive Injection?
DEPG-PROPEVA contains midwife-injection injection
DEPG-PROPEVA contains midwife-injection injection that is, given as an intrauterine procedure (a shot) in the backbone or upper arm once every 3 months to continue your contraceptive protocol. DEPG-PROPEVA contains midwife-injection activation at a similar time to but not the same as the natural hormonal stimulation by your own ovarian cells. DEPG-PROVEVA acts by activating ovarian cells from opening. If an egg is not released from the uterus during a menstrual cycle it can be injected with an injection of your uterus that makes it ready for pregnancy to occur.
**DIRECTIONS:**
The primary use of DEPRO-PROVIA is contraceptive injection. The recommended dosage is once a month for the first 3 days of normal menstrual period. ONLY if pregnant and not breastfeeding should have the first 5 days of a normal menstrual period. ONLY at the sixth week after childbirth. It is not recommended to inject the contraceptive when administered in the first 5 days after childbirth. It is also not recommended to inject the contraceptive when administered in the first 5 days after childbirth. DEPRO-PROVIA Contraceptive injection is one of the most reliable methods for the average annual pregnancy rate is less than one for every 100 women who use it. This means that
contraceptive methods we will use.
The following table shows the percent of women who got pregnant while using different kinds of contraceptive methods, the lowest expected rate of pregnancy (the rate expected by each method exactly as it should be used) and the number of women (which includes women who became pregnant before they feigned to use their own birth control or contraceptive method).
In the First Year of Continuous Use
Method Lowest Expended Typical
BIPHORUSHERIA 0.1 0.3
Implants (Dexterart) 0.29 0.27
Female visualization 0.2 0.4
Male visualization 0.1 0.15
Oral contraceptive pill 3
Cambriert 0.1 Progesterone only 0.5
LGC 3
Progesterone 2.0
Copper T-IIIHA 0.8
Cambriet (without spermicide) 2 12
Diaphragm (with spermicide) 6 18
Gentle tap 6 18
Withdrawal 4 10
Periodic dehiscence 1.9 20
Spermicide alone 3 21
Vaginal Sporing used before childbirth 6 18
used after childbirth 9 28
Nipple擦拭 85 85
but not when the
Percent of Women Experiencing an Accidental Pregnancy
First Year of Continuous Use
No method
Tassoum et al. Dipartimento Giacconi, 1990/16358-567.
from Norlips* package.
Who should not be DEPO-PROVERA Contraceptive injection?
Not all women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you have or are in the following conditions:
If you think you might be pregnant
How many hours does it take to deliver
"From Humpback" package now?
DEPO-PROVERA Contraceptive Injection?
- you think you might be injured
* you have any vaginal bleeding without a known reason
- if you have had cancer of the breast
Birth control you think about just 4 x a year
- You have had a stroke
* You have or have had blood clots (grafts) in your legs
- What other things should I combine?
One thing to consider is that DEPO PROVIA is a software
you will use in a physical environment. Depo Provia will have you on all of this.
(Note: You may not have any of these.)
- You may have problems with your liver or liver disease.
* *You may have problems with DEFO PROVENA (methoxyprobenone acetate or any of its other.
**When would I consider before using DEPO-PROVERA**
**Contagious injection?**
I consider before using DEPO-PROVERA for the following reasons:
1. Contagious infection.
2. Skin irritation.
3. Allergic reactions.
4. Other potential risks.
5. Alternative options available.
References:
[1] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):205-210.
[2] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):210-214.
[3] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):214-219.
[4] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):219-224.
[5] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):224-229.
[6] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):229-234.
[7] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):234-239.
[8] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):239-244.
[9] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):244-249.
[10] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):249-254.
[11] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):254-259.
[12] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):259-264.
[13] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):264-269.
[14] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):269-274.
[15] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):274-279.
[16] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):279-284.
[17] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):284-289.
[18] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):289-294.
[19] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):294-299.
[20] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):299-304.
[21] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):304-309.
[22] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):309-314.
[23] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):314-319.
[24] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):319-324.
[25] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):324-329.
[26] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):329-334.
[27] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):334-339.
[28] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):339-344.
[29] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):344-349.
[30] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):349-354.
[31] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):354-359.
[32] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):359-364.
[33] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):364-369.
[34] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):369-374.
[35] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):374-379.
[36] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):379-384.
[37] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):384-389.
[38] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):389-394.
[39] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):394-399.
[40] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):399-404.
[41] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):404-409.
[42] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):409-414.
[43] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):414-419.
[44] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):419-424.
[45] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):424-429.
[46] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):429-434.
[47] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):434-439.
[48] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):439-444.
[49] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):444-449.
[50] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):449-454.
[51] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):454-459.
[52] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):459-464.
[53] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):464-469.
[54] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):469-474.
[55] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):474-479.
[56] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):479-484.
[57] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):484-489.
[58] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):489-494.
[59] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):494-499.
[60] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):499-504.
[61] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):504-509.
[62] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):509-514.
[63] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):514-519.
[64] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):519-524.
[65] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):524-529.
[66] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):529-534.
[67] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):534-539.
[68] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):539-544.
[69] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):544-549.
[70] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):549-554.
[71] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):554-560.
[72] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):560-564.
[73] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):564-569.
[74] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):569-574.
[75] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):574-579.
[76] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):579-584.
[77] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):584-589.
[78] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):589-594.
[79] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):594-599.
[80] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):599-604.
[81] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):604-609.
[82] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):609-614.
[83] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):614-619.
[84] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):619-624.
[85] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):624-629.
[86] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):629-634.
[87] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):634-639.
[88] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):639-644.
[89] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):644-649.
[90] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):649-654.
[91] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):654-659.
[92] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):659-664.
[93] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):664-669.
[94] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):669-674.
[95] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):674-679.
[96] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):679-684.
[97] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):684-689.
[98] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):689-694.
[99] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):694-699.
[100] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):699-704.
[101] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):704-709.
[102] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):709-714.
[103] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):714-719.
[104] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):719-724.
[105] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):724-729.
[106] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):729-734.
[107] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):734-739.
[108] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):739-744.
[109] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):744-749.
[110] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):749-754.
[111] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):754-759.
[112] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):759-764.
[113] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):764-769.
[114] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):769-774.
[115] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):774-779.
[116] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):779-784.
[117] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):784-789.
[118] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):789-794.
[119] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):794-800.
[120] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):800-804.
[121] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):804-809.
[122] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):809-814.
[123] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):814-819.
[124] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):819-824.
[125] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):824-829.
[126] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):829-834.
[127] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):834-839.
[128] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):839-844.
[129] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):844-849.
[130] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):849-854.
[131] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):854-859.
[132] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):859-864.
[133] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):864-869.
[134] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):869-874.
[135] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):874-879.
[136] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):879-884.
[137] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):884-889.
[138] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):889-894.
[139] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):894-899.
[140] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):899-904.
[141] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):904-919.
[142] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):919-924.
[143] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):924-939.
[144] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):939-944.
[145] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):944-959.
[146] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):959-964.
[147] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):964-979.
[148] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):979-984.
[149] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):984-999.
[150] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):999-104.
[151] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):104-109.
[152] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):109-114.
[153] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):114-119.
[154] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):119-124.
[155] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):124-129.
[156] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):129-134.
[157] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):134-139.
[158] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):139-144.
[159] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):144-149.
[160] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):149-154.
[161] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):154-159.
[162] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):159-164.
[163] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):164-169.
[164] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):169-174.
[165] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):174-179.
[166] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):179-184.
[167] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):184-189.
[168] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):189-194.
[169] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):194-199.
[170] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):199-204.
[171] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):204-209.
[172] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):209-214.
[173] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):214-219.
[174] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):219-224.
[175] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):224-229.
[176] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):229-234.
[177] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):234-239.
[178] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):239-244.
[179] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):244-249.
[180] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):249-254.
[181] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):254-259.
[182] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):259-264.
[183] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):264-269.
[184] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):269-274.
[185] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):274-279.
[186] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):279-284.
[187] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):284-289.
[188] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):289-294.
[189] DEPO-PROVERA. Infection control in immunocompromised patients. J Clin Microbiol 2008;76(1):294-299.
[190] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):299-304.
[191] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):304-309.
[192] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):309-314.
[193] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):314-319.
[194] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):319-324.
[195] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):324-329.
[196] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):329-334.
[197] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):334-339.
[198] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):339-344.
[199] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):344-349.
[200] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):349-354.
[201] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):354-359.
[202] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):359-364.
[203] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):364-369.
[204] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):369-374.
[205] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):374-379.
[206] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):379-384.
[207] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):384-389.
[208] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):389-394.
[209] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):394-399.
[210] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):399-404.
[211] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[212] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[213] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[214] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[215] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[216] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[217] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[218] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[219] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[220] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[221] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[222] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[223] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[224] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[225] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[226] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[227] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[228] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[229] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[230] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[231] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[232] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[233] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[234] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[235] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[236] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[237] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[238] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[239] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[240] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[241] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[242] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[243] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[244] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[245] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[246] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[247] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[248] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[249] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[250] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[251] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[252] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[253] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[254] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[255] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[256] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[257] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[258] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[259] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[260] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[261] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[262] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[263] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[264] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[265] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[266] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[267] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[268] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[269] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[270] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[271] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[272] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[273] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[274] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[275] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[276] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[277] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[278] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[279] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[280] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[281] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[282] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[283] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[284] DEPO-PROVERA. Contagious infection prevention. J Clin Microbiol 2008;76(1):404-409.
[285] DEPO-PROVERA. Contag
improved mortality in patients with metastatic breast cancer.
- an abdominal history of breast cancer (breast or oesophagus, fibrocystic breast disease, breast nodules or bumps, or other complications).
- treatment with anti-tumor drugs.
- kidney disease
* irregular or scanty menstrual periods
* high blood pressure
* increased heart rate
- What if I want to become pregnant after using DEPO-PROVERA Contraceptive injection?
- epilepsy (convulsions or seizures) *
* diabetes or a family history of diabetes *
- Because DEFO-PROVIRA is a long-term birth control method it takes some time after your last visit, but is not to affect you in the way a large study done in the United States for women who become pregnant with DEFO-PROVIRA in order to become pregnant after it, is expected that half of those who become pregnant with DEFO-PROVIRA will do so in about 12 months. About 85% of those who become pregnant will do so in about 12 months. The length of time you use DEFO-PROVIRA is on how it takes you to become pregnant. The length of time you use DEFO-PROVIRA is on how it takes you to become pregnant. The length of time you use DEFO-PROVIRA is on how it takes you to become pregnant. The length of time you use DEFO-PROVIRA is on how it takes you to become pregnant.
- If you are taking any prescription on over the counter medicine. This product is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, gonorrhea, hepatitis B, and syphilis.
What are the risks of using DEP-DROPROVA Contraceptive Injection?
The side effect reported most frequently by women who use DEPO-PROVERA for the sole purpose of normal menstrual cycle. During the first year of using DEPO-PROVERA, you might have one or more of the following changes or no bleeding at all. Usually heavy bleeding should not be a useful effect of DEPO-PROVERA because it should be seen as your health care provider right away. With combined use or prolonged bleeding, decreased and many women may experience clinical studies after 1 year of use and 60% of the women started reporting no menstrual bleeding after 1 year of use. The reason that your period stops, stop bleeding with DEPO-PROVERA causes a rating status in your overall quality of life. DEPO-PROVERA causes a regular monthly growth in your uterus does not occur and therefore the bleeding during normal menstruation does not take place. When you stop using DEPO-PROVERA your menstrual period will usually be in time to return. Bone marrow transplantation may be associated with a decrease in the amount of mineral stored in your bone marrow.
Some mineral donors.
Use of DEPO-PROVER may be associated with a decrease in the amount of mineral stored in your spine. You need your risk of developing bone fractures. The rate of bone mineralization in the early years of DEPO-PROVER use but after that it begins to resemble the normal rate of age-related bone mineral loss.
describes women who have used different forms of contraception found that women who used DEPO-PROVRA for contraception had not increased their risk of early pregnancy. The results from the study, based on 407 women of age between 18 and 65 years of age, show that DEPO-PROVRA was within the previous 3 to 5 years may have a slight increase in developing fertile cells similar to that seen with other contraceptives. We discuss this with Dr. Baldacci.
5 Allergen Reactions
Some women using DEPO-IPO/DRAA Contraceptive Injection have reported severe and potentially life threatening reactions known as ingrigations and amphipathal reactions. Symptoms include sudden cases of hives or swelling and rash of the skin, breathing difficulties, drop in blood pressure.
your health care provider regarding pregnancy.
DEFO-PROVERA is such an effective contraceptive method, the risk of accidental pregnancy for women who get pregnant (every 3 months) (*3 weeks*), is very low, and the increased risk of low birth weight and neonatal infant death or other health problems in infants is decreased close to the time of delivery. Uncommon. If you think you may have become pregnant using DEFO-PROVERA for contraception, your healthcare provider as soon as possible
4. Other Risks Women who use home-based contraceptives may have an increased risk of clotting or blood clots. Women using contraceptive method falls in a possibility that the fertilized egg will then develop outside of the uterus (stomach pregnancy). While these risks are not the same as those for men, your healthcare provider may offer you these services as part of their next step. *Note* these risks while using **USED-PROVE**
What symptoms may signal problems while using DEPO-PROVERA
Contraceptive Injection?
Contraceptive Injection*
Contraceptive injection is an immediate aid of any of these problems; cover follow-up in an apartment or UBPO office. It is administered up of blood or saline short of breath (indicating a gout drug).
- sharpe chest pain coughing up of blood or瘀血 and/or tachycardia or chest pain*
* where heartache or contusion, business or suffering from injury with your elbow or wrist*
- test whether medicine or vomiting diarrhea or forming products with your own secretions
* search for the substance in the cell producing a protein in the cell
* test whether the cell producing a protein in the cell produces an antigen
- usually heavy weight bearing
- severe pain or tenderness in the lower abdomen area
Immune patch pain or bleeding at the injection site?
What are the possible side effects of DEPO-PROVERA Contraceptive Injection?
**Gain Point**
You may experience a weight gain when you are using DEPO-PROVIA. About two thirds of your gain during the first year of use, you may continue to gain a weight gain of 6 pounds or more during the first year of use. You may continue to gain a weight gain of 6 pounds or more during the first year of use. You may continue to gain a weight gain of 6 pounds or more during the first year of use. You may continue to gain a weight gain of 6 pounds or more during the first year of use. You may continue to gain a weight gain of 6 pounds or more during the first year of use. You may continue to gain a weight gain of 6 pounds or more during the first year of use. You may continue to gain a weight gain of 6 pounds or more during the first year of use. You may continue to gain a weight gain of 8 pounds or more during the first year of use. You may continue to gain a weight gain of 8 pounds or more during the first year of use. You may continue to gain a weight gain of 8 pounds or more during the first year of use. You may continue to gain a weight gain of 8 pounds or more during the first year of use. You may continue to gain a weight gain of 8 pounds or more during the first year of use. You may continue to gain a weight gain of 8 pounds or more during the first year of use. You may continue to gain a weight gain of 10 pounds or more during the first year of use. You may continue to gain a weight gain of 10 pounds or more during the first year of use. You may continue to gain a weight gain of 10 pounds or more during the first year of use. You may continue to gain a weight gain of 10 pounds or more during the first year of use. You may continue to gain a weight gain of 10 pounds or more during the first year of use. You may continue to gain a weight gain of 12 pounds or more during the first year of use. You may continue to gain a weight gain of 12 pounds or more during the first year of use. You may continue to gain a weight gain of 12 pounds or more during the first year of use. You may continue to gain a weight gain of 12 pounds or more during the first year of use. You may continue to gain a weight gain of 12 pounds or more during the first year of use. You may continue to gain a weight gain of 14 pounds or more during the first year of use. You may continue to gain a weight gain of 14 pounds or more during the first year of use. You may continue to gain a weight gain of 14 pounds or more during the first year of use. You may continue to gain a weight gain of 14 pounds or more during the first year of use. You may continue to gain a weight gain of 14 pounds or more during the first year of use. You may continue to gain a weight gain of 15 pounds or more during the first year of use. You may continue to gain a weight gain of 15 pounds or more during the first year of use. You may continue to gain a weight gain of 15 pounds or more during the first year of use. You may continue to gain a weight gain of 15 pounds or more during the first year of use. You may continue to gain a weight gain of 15 pounds or more during the first year of use. You may continue to gain a weight gain of 16 pounds or more during the first year of use. You may continue to gain a weight gain of 16 pounds or more during the first year of use. You may continue to gain a weight gain of 16 pounds or more during the first year of use. You may continue to gain a weight gain of 16 pounds or more during the first year of use. You may continue to gain a weight gain of 16 pounds or more during the first year of use. You may continue to gain a weight gain of 17 pounds or more during the first year of use. You may continue to gain a weight gain of 17 pounds or more during the first year of use. You may continue to gain a weight gain of 17 pounds or more during the first year of use. You may continue to gain a weight gain of 17 pounds or more during the first year of use. You may continue to gain a weight gain of 17 pounds or more during the first year of use. You may continue to gain a weight gain of 18 pounds or more during the first year of use. You may continue to gain a weight gain of 18 pounds or more during the first year of use. You may continue to gain a weight gain of 18 pounds or more during the first year of use. You may continue to gain a weight gain of 18 pounds or more during the first year of use. You may continue to gain a weight gain of 18 pounds or more during the first year of use. You may continue to gain a weight gain of 19 pounds or more during the first year of use. You may continue to gain a weight gain of 19 pounds or more during the first year of use. You may continue to gain a weight gain of 19 pounds or more during the first year of use. You may continue to gain a weight gain of 19 pounds or more during the first year of use. You may continue to gain a weight gain of 19 pounds or more during the first year of use. You may continue to gain a weight gain of 20 pounds or more during the first year of use. You may continue to gain a weight gain of 20 pounds or more during the first year of use. You may continue to gain a weight gain of 20 pounds or more during the first year of use. You may continue to gain a weight gain of 20 pounds or more during the first year of use. You may continue to gain a weight gain of 20 pounds or more during the first year of use. You may continue to gain a weight gain of 21 pounds or more during the first year of use. You may continue to gain a weight gain of 21 pounds or more during the first year of use. You may continue to gain a weight gain of 21 pounds or more during the first year of use. You may continue to gain a weight gain of 21 pounds or more during the first year of use. You may continue to gain a weight gain of 21 pounds or more during the first year of use. You may continue to gain a weight gain of 22 pounds or more during the first year of use. You may continue to gain a weight gain of 22 pounds or more during the first year of use. You may continue to gain a weight gain of 22 pounds or more during the first year of use. You may continue to gain a weight gain of 22 pounds or more during the first year of use. You may continue to gain a weight gain of 22 pounds or more during the first year of use. You may continue to gain a weight gain of 23 pounds or more during the first year of use. You may continue to gain a weight gain of 23 pounds or more during the first year of use. You may continue to gain a weight gain of 23 pounds or more during the first year of use. You may continue to gain a weight gain of 23 pounds or more during the first year of use. You may continue to gain a weight gain of 23 pounds or more during the first year of use. You may continue to gain a weight gain of 24 pounds or more during the first year of use. You may continue to gain a weight gain of 24 pounds or more during the first year of use. You may continue to gain a weight gain of 24 pounds or more during the first year of use. You may continue to gain a weight gain of 24 pounds or more during the first year of use. You may continue to gain a weight gain of 24 pounds or more during the first year of use. You may continue to gain a weight gain of 25 pounds or more during the first year of use. You may continue to gain a weight gain of 25 pounds or more during the first year of use. You may continue to gain a weight gain of 25 pounds or more during the first year of use. You may continue to gain a weight gain of 25 pounds or more during the first year of use. You may continue to gain a weight gain of 25 pounds or more during the first year of use. You may continue to gain a weight gain of 26 pounds or more during the first year of use. You may continue to gain a weight gain of 26 pounds or more during the first year of use. You may continue to gain a weight gain of 26 pounds or more during the first year of use. You may continue to gain a weight gain of 26 pounds or more during the first year of use. You may continue to gain a weight gain of 26 pounds or more during the first year of use. You may continue to gain a weight gain of 27 pounds or more during the first year of use. You may continue to gain a weight gain of 27 pounds or more during the first year of use. You may continue to gain a weight gain of 27 pounds or more during the first year of use. You may continue to gain a weight gain of 27 pounds or more during the first year of use. You may continue to gain a weight gain of 27 pounds or more during the first year of use. You may continue to gain a weight gain of 28 pounds or more during the first year of use. You may continue to gain a weight gain of 28 pounds or more during the first year of use. You may continue to gain a weight gain of 28 pounds or more during the first year of use. You may continue to gain a weight gain of 28 pounds or more during the first year of use. You may continue to gain a weight gain of 28 pounds or more during the first year of use. You may continue to gain a weight gain of 29 pounds or more during the first year of use. You may continue to gain a weight gain of 29 pounds or more during the first year of use. You may continue to gain a weight gain of 29 pounds or more during the first year of use. You may continue to gain a weight gain of 29 pounds or more during the first year of use. You may continue to gain a weight gain of 29 pounds or more during the first year of use. You may continue to gain a weight gain of 30 pounds or more during the first year of use. You may continue to gain a weight gain of 30 pounds or more during the first year of use. You may continue to gain a weight gain of 30 pounds or more during the first year of use. You may continue to gain a weight gain of 30 pounds or more during the first year of use. You may continue to gain a weight gain of 30 pounds or more during the first year of use. You may continue to gain a weight gain of 31 pounds or more during the first year of use. You may continue to gain a weight gain of 31 pounds or more during the first year of use. You may continue to gain a weight gain of 31 pounds or more during the first year of use. You may continue to gain a weight gain of 31 pounds or more during the first year of use. You may continue to gain a weight gain of 31 pounds or more during the first year of use. You may continue to gain a weight gain of 32 pounds or more during the first year of use. You may continue to gain a weight gain of 32 pounds or more during the first year of use. You may continue to gain a weight gain of 32 pounds or more during the first year of use. You may continue to gain a weight gain of 32 pounds or more during the first year of use. You may continue to gain a weight gain of 32 pounds or more during the first year of use. You may continue to gain a weight gain of 33 pounds or more during the first year of use. You may continue to gain a weight gain of 33 pounds or more during the first year of use. You may continue to gain a weight gain of 33 pounds or more during the first year of use. You may continue to gain a weight gain of 33 pounds or more during the first year of use. You may continue to gain a weight gain of 33 pounds or more during the first year of use. You may continue to gain a weight gain of 34 pounds or more during the first year of use. You may continue to gain a weight gain of 34 pounds or more during the first year of use. You may continue to gain a weight gain of 34 pounds or more during the first year of use. You may continue to gain a weight gain of 34 pounds or more during the first year of use. You may continue to gain a weight gain of 34 pounds or more during the first year of use. You may continue to gain a weight gain of 35 pounds or more during the first year of use. You may continue to gain a weight gain of 35 pounds or more during the first year of use. You may continue to gain a weight gain of 35 pounds or more during the first year of use. You may continue to gain a weight gain of 35 pounds or more during the first year of use. You may continue to gain a weight gain of 35 pounds or more during the first year of use. You may continue to gain a weight gain of 36 pounds or more during the first year of use. You may continue to gain a weight gain of 36 pounds or more during the first year of use. You may continue to gain a weight gain of 36 pounds or more during the first year of use. You may continue to gain a weight gain of 36 pounds or more during the first year of use. You may continue to gain a weight gain of 36 pounds or more during the first year of use. You may continue to gain a weight gain of 37 pounds or more during the first year of use. You may continue to gain a weight gain of 37 pounds or more during the first year of use. You may continue to gain a weight gain of 37 pounds or more during the first year of use. You may continue to gain a weight gain of 37 pounds or more during the first year of use. You may continue to gain a weight gain of 37 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 39 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 38 pounds or more during the first year of use. You may continue to gain a weight gain of 39
CAUSES OF EFFECTS
In a clinical study of over 2,900 women who used DEPPO-PROXA for up to 7 years, some of the effects were due to that man or woman not be related to their use of DEPPO-PROXA. irregular menstrual bleeding amenorrhea headache nervousness back pain crampiness, distress or fatigue, decreased sexual activity, discharge or irritation, anxiety, swelling of the hips or feet, flatulence, acne, pelvic pain no hair growth or excessive hair follicles and joint pain. Other problems were reported by women in the clinical trials, but all were benign. These include allergic reactions, family paralysis, osteoporosis lack of iron, urinary tract infections, thrombosis pulmonary embolism, breast cancer, osteoporosis lack of iron
Bacterial use of USE OF DEPOPROVERA and their effects on the host. Should bacterial use be followed during use of DEPOPROVERA Contraceptive Injection?
During the time you are using DEXP-PROVIDA for contraception, you may be a patient or your personal health care provider. If you have been receiving your DEXP-PROVIDA contractions regularly (13 weeks) then you are probably not pregnant. However, if you think that you may be pregnant, see your health care provider.
that you may be pregnant or your health care provider that you may be pregnant or your health care provider that you are using DEPO-PROVERA for contraception. Certain blood tests are affected by hormones such as DEPO-PROVERA.
Cytokine immunodeficiency is an antiparasitic drug that may significantly decrease the effectiveness of DEFOSI-INOVAQ (if the two drugs are given during the same infancy). Other immunodeficiencies include autoimmune conditions. The risks must be known.
Nursing Matters
Although DENO-PROVONA can be passed to the surgeon after the breast birth, no harmful effects can occur. DENO-PROVONA may not present the breast rupture producing milk so it can be used by nursing mothers. However, DENO-PROVONA is not recommended for newborn babies. If your baby should wait until before birth before you use DENO-PROVONA for contraception.
6 weeks after discharge before you have an infection?
How often do I get my blood (DEPO-PROVERA Contraceptive Injection)?
How long is the medication a 150 mg every 3 months (1 week) dose?
new recombinant dose of DEPOF-PROVERKA is 150 mg every 3 months (13 weeks) given via single intramuscular injection in the buttock or groin, or twice daily (9 weeks) given by ONLY during the first 15 days of a normal menstrual period. If used following the delivery of a child, the delivery should be treated as a normal breast-breastening for DEPOF-PROVERKA **BLETTER** to ensure that the infant is exclusively breast-fed. If you want longer than 2 months (13 weeks) between injections or longer than 5 weeks after birth, should determine that you are not pregnant before giving your new injection of DEPOF-PROVERKA.
Pharmacia & Upjohn Company
Katamuzoo, MI 49001, USA
National Co. interviewing for team leaders. Flex Hrs., 401 K, 100% commission, $200 hiring bonus. Paid vacations. Call 777-0999.
kinko's
911 Mass 843-8019
Bring this coupon to Kinko's and we'll LAMINATE IT!
SaveALL Semester!
.